Dublin, April 18, 2024 (GLOBE NEWSWIRE) -- The "Opioid-Induced Constipation - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.The report covers ...

The Global Opioid Induced Constipation Market size was estimated at USD 62.12 million in 2022, USD 65.95 million in 2023, and is projected to grow at a CAGR of 6.62% to reach USD 103.78 million by ...

RELISTOR (methylnaltrexone bromide) Subcutaneous Injection is a first-in-class treatment for opioid-induced constipation approved in the United States for patients with chronic non-cancer pain ...

The most common adverse reactions (≥ 12%) in adult patients with opioid-induced constipation and chronic non-cancer pain receiving RELISTOR tablets were abdominal pain, diarrhea, headaches ...

The Global Opioid Induced Constipation (OIC) Drugs Market is valued approximately at USD 1.21 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 5.01 % over the ...

However, naloxegol (Movantik) is specifically for opioid-induced constipation. It works exclusively in the bowel. Since it is not absorbed, it does not cause withdrawal symptoms.

Naldemedine for opioid-induced constipation in patients with cancer: A multicenter, double-blind, randomized, placebo-controlled trial Journal: Journal of Clinical Oncology DOI: 10.1200/JCO.24.00381 ...

Naldemedine for Opioid-Induced Constipation in Patients With Cancer: A Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial The article by Hamano et al entitled “Naldemedine for ...

The Food and Drug Administration recently approved the tablet form of Relistor to treat opioid-induced constipation. Relistor, produced by Tarrytown, N.Y.-based Progenics Pharmaceuticals, was ...

APS 2009: Opioid-Induced Constipation Highly Prevalent Allison Gandey May 12, 2009 0 ...

Evidence-based recommendations on naloxegol (Moventig) for treating opioid-induced constipation in adults. Last reviewed: 9 July 2018 We checked this guidance and found nothing new that affects the ...

Decision to move the existing guidance to the static list We would like to update you on the decision made regarding the review of the existing guidance on TA345; Naloxegol for treating opioid induced ...